Focused on new deals, Biogen bags a PhIII drug for ischemic stroke with $120M upfront
Biogen’s business development team has been on the march.
The big biotech has struck a deal to buy a Phase III drug for ischemic stroke for $120 million up front, looking to oversee the late-stage program aimed at expanding its portfolio of neuroscience drugs.
Biogen bought the drug from Remedy Pharmaceuticals, which completed the mid-stage effort and gathered orphan and fast track status for Cirara. The drug tackles SUR1-TRPM4 channels, hitting a pathway involved in brain swelling, or cerebral edema. And it will now be put alongside natalizumab, a Biogen therapy now in Phase IIb for inflammation related to ischemic stroke.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
